Tests daraxonrasib against docetaxel in previously treated lung cancer with RAS mutations
Compares daraxonrasib with docetaxel in adults with previously treated RAS-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Key facts
- Where
- Aberdeen, Ann Arbor, Athens, Atlanta, Austin, Baltimore, Bettendorf, Billings, Birmingham, Buffalo, Chapel Hill, Chicago, Cincinnati, Colorado Springs, Dallas, Detroit, Eugene, Fairfax, Fort Myers, Hackensack, Henderson, Hershey, Houston, Indianapolis, Iowa City, Irving, Lebanon, Loma Linda, Long Beach, Maumee, Morristown, Nashville, New Haven, New York, Orange, Plantation, Salt Lake City, Sioux Falls, St Louis, St. Petersburg, Stuart, The Bronx, The Woodlands, Waukee, West Palm Beach, and Westwood, United StatesSee the 53 sites
- Phase
- Phase 3
Where in United States
- Avera Saint Luke's HospitalAberdeen, United StatesNo longer taking part
- Trinity Health Ann Arbor HospitalAnn Arbor, United StatesNo longer taking part
- University Cancer and Blood CenterAthens, United StatesNo longer taking part
- Piedmont Healthcare, IncAtlanta, United StatesNo longer taking part
- Winship Cancer InstituteAtlanta, United StatesNo longer taking part
- Texas Oncology South AustinAustin, United StatesNo longer taking part
- Johns Hopkins University of MedicineBaltimore, United StatesNo longer taking part
- University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United StatesNo longer taking part
- University of Iowa Health Care Cancer Services Quad CitiesBettendorf, United StatesNo longer taking part
- St. Vincent Frontier Cancer CenterBillings, United StatesNo longer taking part
- Alabama OncologyBirmingham, United StatesNo longer taking part
- Roswell Park Cancer InstituteBuffalo, United StatesNo longer taking part
- UNC Lineberger Comprehensive Cancer Center at University of North CarolinaChapel Hill, United StatesNo longer taking part
- Rush University Medical CenterChicago, United StatesNo longer taking part
- University of Chicago Medical CenterChicago, United StatesNo longer taking part
- University of Illinois Cancer CenterChicago, United StatesNo longer taking part
- TriHealth Cancer & Blood Institute ResearchCincinnati, United StatesNo longer taking part
- UCHealth Memorial Hospital CentralColorado Springs, United StatesNo longer taking part
- Texas Oncology - DallasDallas, United StatesNo longer taking part
- Brigitte Harris Cancer Pavilion BHCPDetroit, United StatesNo longer taking part
- Karmanos Cancer InstituteDetroit, United StatesNo longer taking part
- Oncology Associates Of Oregon, PcEugene, United StatesNo longer taking part
- Virginia Cancer SpecialistsFairfax, United StatesNo longer taking part
- Florida Cancer Specialists & Research Institute - SouthFort Myers, United StatesNo longer taking part
- John Theurer Cancer Center At Hackensack UMCHackensack, United StatesNo longer taking part
- Comprehensive Cancer Centers of NevadaHenderson, United StatesNo longer taking part
- Penn State Milton S. Hershey Medical CenterHershey, United StatesNo longer taking part
- MD Anderson Cancer CenterHouston, United StatesNo longer taking part
- Community Health NetworkIndianapolis, United StatesNo longer taking part
- University of Iowa Hospitals & ClinicsIowa City, United StatesNo longer taking part
- Cancer Care Centers of BrevardIrving, United StatesNo longer taking part
- US Oncology Investigational Products Center (IPC)Irving, United StatesNo longer taking part
- Dartmouth Hitchcock Medical CenterLebanon, United StatesNo longer taking part
- Loma Linda UniversityLoma Linda, United StatesNo longer taking part
- MemorialCare Long Beach Medical CenterLong Beach, United StatesNo longer taking part
- Taylor Cancer Research CenterMaumee, United StatesNo longer taking part
- Morristown Medical Center (MMCORC)Morristown, United StatesNo longer taking part
- SCRI Oncology Partners - TennesseeNashville, United StatesNo longer taking part
- Yale University, Smillow Cancer CenterNew Haven, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- UC Irvine HealthOrange, United StatesTaking people
- BRCR globalPlantation, United StatesNo longer taking part
- Huntsman Cancer InstituteSalt Lake City, United StatesNo longer taking part
- Utah Cancer SpecialistsSalt Lake City, United StatesNo longer taking part
- Avera Cancer InstituteSioux Falls, United StatesNo longer taking part
- Washington University School of Medicine - Siteman Cancer CenterSt Louis, United StatesNo longer taking part
- Florida Cancer Specialists & Research Institute - NorthSt. Petersburg, United StatesNo longer taking part
- Cleveland Clinic Martin NorthStuart, United StatesNo longer taking part
- Montefiore Medical CenterThe Bronx, United StatesNo longer taking part
- Texas Oncology- Gulf CoastThe Woodlands, United StatesNo longer taking part
- University of Iowa Health Care, Mission Cancer + BloodWaukee, United StatesNo longer taking part
- Florida Cancer Specialists & Research Institute - EastWest Palm Beach, United StatesNo longer taking part
- The University of Kansas Cancer CenterWestwood, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06881784EU 2024-518154-16-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.Read full original descriptionShow less
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Inclusion: At least 18 years old and has provided informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy; Measurable disease per RECIST v1.1; Adequate organ function (bone marrow, liver, kidney, coagulation); One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy; Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61); Able to take oral medications.
Exclusion: Prior therapy with direct RAS-targeted therapy or docetaxel; Ongoing anticancer therapy; Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function); Untreated central nervous system (CNS) metastases; Pregnant or breastfeeding.